Waismann Method® Applauds FDA’s Opioid Label Changes but Cautions New Guidelines Are Not Enough BEVERLY HILLS, Calif., April 10, 2019 — The U.S. Food and Drug Administration’s recent efforts to stem the tide of the opioid epidemic have received backlash from pain management doctors and chronic pain patients. By curtailing access to prescription opioids for […]
Get Newsletter Updates from Waismann Method®
"*" indicates required fields
We are available 7 days a week
DISCLAIMER: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional. Be advised that Opiates.com articles are derived from various sources and may not reflect your own country’s regulations.
